VA-INTELSAT
23.5.2024 15:31:29 CEST | Business Wire | Press release
Intelsat, operator of one of the world’s largest integrated satellite and terrestrial networks and leading provider of inflight connectivity (IFC), will deliver years of additional reliable broadband, video distribution and mobile satellite service to customers across three continents thanks to the success of Northrop Grumman’s innovative Mission Extension Vehicle (MEV) that will ultimately provide an expected additional nine years of life to the Intelsat 10-02 (IS-10-02) geosynchronous satellite.
Geosynchronous Earth orbit (GEO) satellites have an average lifespan of about 15-20 years before they start running low on fuel. Intelsat in 2020 became the first satellite operator to commit to deploying two of Northrop Grumman’s MEVs to extend the life of an otherwise healthy satellite. Both MEVs have been successful at their mission and have allowed IS-10-02 and Intelsat 901 (IS-901) to provide five years of service beyond the expected lifespan of the satellite. Under amendments to the original agreements with Northrop Grumman’s SpaceLogistics LLC, both MEVs will stay in space serving Intelsat satellites for several more years, allowing them to operate longer.
- At the end of the current servicing period, MEV-1 will release the IS-901 satellite into the GEO graveyard and then provide service for another Intelsat satellite.
- MEV-2 will remain docked to Intelsat’s current vehicle, IS-10-02, providing life-extension for several years – nearly doubling service from the original contract. The IS-10-02 satellite was manufactured by Airbus Defense & Space, was launched in June 2004 and entered service in August 2004. Capacity on the satellite is shared with Telenor Satellite. Today, MEV-2 is helping to extend the life of IS-10-02, so the satellite can continue providing high-quality media distribution and broadband services to our customers across Europe, the Middle East, Africa and South America. IS-10-02 is a key satellite in the Intelsat-Telenor Satellite video neighborhood, distributing more than 900 channels to nearly 18 million television households across Europe.
“As the largest satellite operator in geosynchronous orbit, Intelsat has always been committed to continuous reliable service, as well as leadership in furthering sustainable space operations,” said Jean-Luc Froeliger, SVP Space Systems at Intelsat. “Intelsat continues to pursue first-of-their-kind innovations to extend the life of its satellites in orbit, while also bringing the industry together to foster information sharing and collaboration across a challenging regulatory environment to achieve sustainable stewardship of the resource of space.”
“This extension is excellent news for our many clients across Europe and the Middle East who are served by THOR 10-02,” said Morten Tengs, CEO of Telenor Satellite. “We pride ourselves on the resilience of our service and, by extending the life of the satellite, we can ensure continuity and hassle-free operations for a number of years.”
MEV Background
In 2020, MEV-1 successfully docked with the IS-901 satellite, a high-performing satellite that was running low on fuel. That marked the first time that two commercial spacecraft docked and began mission-extension service in GEO. The in-space maneuver pointed IS-901 to targeted antennas on Earth and extended its life for another five years of its lifespan.
In 2021, the feat was repeated with a second MEV-2 docking with the IS-10-02 satellite. Unlike the first docking, which was performed in a graveyard orbit a few hundred kilometers above active satellites, this time the MEV-2 docked with IS-10-02 in its original orbital slot and avoided any interruption of services to customers, resulting in the first-ever in-orbit servicing of a live commercial satellite in GEO.
About Intelsat
Intelsat’s global team of professionals is focused on providing seamless and secure, satellite-based communications to government, NGO and commercial customers through the company’s next-generation worldwide network and managed services. Bridging the digital divide by operating one of the world’s largest and most advanced satellite fleet and connectivity infrastructures, Intelsat enables people and their tools to speak over oceans, see across continents and listen through the skies to communicate, cooperate and coexist. Since its founding six decades ago, the company has been synonymous with satellite-industry “firsts” in service to its customers and the planet. Leaning on a legacy of innovation and focusing on addressing a new generation of challenges Intelsat team members now have their sights on the “next firsts” in space as they disrupt the field and lead in the digital transformation of the industry.
Follow Us on Social Media:
X | LinkedIn | Instagram | YouTube
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523619448/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release
Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
